Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
217.5 USD | +1.87% | +4.12% | -15.94% |
May. 03 | HSBC Adjusts Price Target on Biogen to $342 From $339, Maintains Buy Rating | MT |
Apr. 30 | Wall Street: buoyed by Tesla, confident ahead of FOMC meeting | CF |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- With an enterprise value anticipated at 3.64 times the sales for the current fiscal year, the company turns out to be overvalued.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-15.94% | 31.67B | B- | ||
-3.79% | 88.14B | A- | ||
+1.45% | 40.51B | A- | ||
+52.66% | 24.62B | A | ||
-14.50% | 15.65B | C | ||
-9.12% | 11.97B | D+ | ||
-14.38% | 12.07B | B- | ||
-42.56% | 11.61B | B | ||
+4.87% | 8.81B | B+ | ||
-4.33% | 8.5B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- BIIB Stock
- Ratings Biogen Inc.